- Home
- AEON vs CARA Comparison
AEON vs CARA Comparison
Compare AEON & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- CARA
- Stock Information
- Founded
- AEON N/A
- CARA 2004
- Country
- AEON United States
- CARA United States
- Employees
- AEON N/A
- CARA N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- CARA Health Care
- Exchange
- AEON Nasdaq
- CARA Nasdaq
- Market Cap
- AEON 38.4M
- CARA 17.7M
- IPO Year
- AEON N/A
- CARA 2014
- Fundamental
- Price
- AEON $0.73
- CARA $0.26
- Analyst Decision
- AEON Strong Buy
- CARA Hold
- Analyst Count
- AEON 1
- CARA 4
- Target Price
- AEON $5.00
- CARA $1.00
- AVG Volume (30 Days)
- AEON 97.3K
- CARA 384.3K
- Earning Date
- AEON 11-11-2024
- CARA 11-11-2024
- Dividend Yield
- AEON N/A
- CARA N/A
- EPS Growth
- AEON N/A
- CARA N/A
- EPS
- AEON 0.99
- CARA N/A
- Revenue
- AEON N/A
- CARA $10,996,000.00
- Revenue This Year
- AEON N/A
- CARA N/A
- Revenue Next Year
- AEON N/A
- CARA $12.57
- P/E Ratio
- AEON $0.75
- CARA N/A
- Revenue Growth
- AEON N/A
- CARA N/A
- 52 Week Low
- AEON $0.71
- CARA $0.24
- 52 Week High
- AEON $17.17
- CARA $2.48
- Technical
- Relative Strength Index (RSI)
- AEON 31.89
- CARA 34.10
- Support Level
- AEON $0.72
- CARA $0.26
- Resistance Level
- AEON $0.89
- CARA $0.33
- Average True Range (ATR)
- AEON 0.07
- CARA 0.02
- MACD
- AEON 0.01
- CARA -0.01
- Stochastic Oscillator
- AEON 12.01
- CARA 10.92
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.